Chiltern expands in diabetes after a big buyout

CRO Chiltern, in the process of integrating its latest acquisition, is focusing in on endocrinology and metabolism, broadening its expertise with an eye on diabetes R&D.

The U.K. company is expanding its service offering and bringing in an outside expert from a rival company to guide the way. Chiltern recruited Randy Anderson, a former vice president for metabolics at PPD, to serve as its senior vice president of scientific affairs. In his 18 years at PPD, Anderson led the CRO's work in endocrinology and metabolism, eventually becoming a board director at JDRF, Chiltern said.

At Chiltern, Anderson's role will be to lead the company's efforts in those fields while at once managing the CRO's scientific affairs experts in all therapeutic areas.

Beyond Anderson's hiring, "expanding our clinical development services for endocrinology and metabolism diseases is a direct response to client desire for collaborative partnerships in development planning, design and execution of clinical trials in this complex therapeutic area," Chiltern CEO Jim Esinhart said in a statement.

Chiltern nearly doubled its size in August after paying an undisclosed sum for Theorem Clinical Research, bringing in that company's roughly 1,500 workers in the Americas, Europe and Asia.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.